Neovascular age-related macular degeneration: 18-month outcomes of aflibercept treatment in patients resistant to ranibizumab
Journal Title: The European Research Journal - Year 2019, Vol 5, Issue 6
Abstract
Objectives: Aim of this study is to investigate the effect of intravitreal aflibercept therapy in an 18-month period in patients with recurrent neovascular age-related macular degeneration resistant to intravitreal ranibizumab. Methods: This is a prospective study of eyes with neovascular age-related macular degeneration switched to intravitreal aflibercept with at least 18 month of follow-up after the switch. All patients had had a minimum of 6 injections of ranibizumab before the switch. All patients received a loading dose of three intravitreal 2 mg aflibercept injections at 4-week intervals. Changes in best-corrected visual acuity, central macular thickness and the frequency of injections were compared. Results: The study included 39 patients, each with one diseased eye. The studied eyes had received an average of 10.74 ± 4.38 previous intravitreal ranibizumab injections over a period of 28.31 ± 18.08 months. During the study, an average of 6.94 ± 2.58 intravitreal aflibercept injections were given in a period of 18 months. Mean central macular thickness at baseline, before switching to aflibercept, 6, 12, and 18 months after the aflibercept injection were 327.44 ± 120.57, 354.50 ± 127.79, 290.20 ± 112.25, 311.70 ± 119.47, and 299.29 ± 98.38 μm, respectively. A significant change was found in the macular thickness measured at intervals throughout the study. However, no significant improvement was found in visual acuity after 18 month after switching to aflibercept. Conclusions: Switching from intravitreal ranibizumab, an inhibitor of vascular endothelial growth factor-A, to aflibercept, another inhibitor for such factors, has increased central macular thickness significantly without changes in visual acuity.
Authors and Affiliations
Elif Ertan, Mustafa Doğan
Keywords
Related Articles
- EP ID EP665250
- DOI 10.18621/eurj.446300
- Views 93
- Downloads 0
Cardiac rehabilitation
Cardiovascular diseases are one of the majorcause of mortality globally. Coronary heart disease is the largest subset of cardiovascular disease. Although mortality rates decline during time, hospital discharge data as a...
Associations of glycated hemoglobin (HbA1c) level with central corneal and macular thickness in diabetic patients without macular edema
Objectives: To determine the correlation between central corneal thickness (CCT) and central macular thickness (CMT), and fasting plasma glucose levels and HbA1c levels before diabetic macular edema (DME) in type 2 diabe...
Tissue eosinophilia: a histopathological marker associated with stromal invasion but not histopathological grade in cutaneous squamous neoplasia
Objectives. The literature does not include any comparative study on the eosinophil count in premalignant and malignant cutaneous squamous neoplasias. Our aim was to compare the tissue eosinophilic count in actinic kerat...
Pathological analysis of cystic lesions of the bones: a retrospective single-center 10-year overview
Objective: Many different neoplastic and non-neoplastic lesions involve the skeletal system. Clinical and radiological tools primarily assess the nature of these lesions.The aim of this study was to analyze the cystic bo...
Primary cardiac B-cell lymphoma
Primary tumors of the heart are very uncommon and approximately 25% of them are malign. Primary cardiac lymphomas account for approximately 4% of the primary cardiac tumors. Both B- and T-cell lymphomas have been reporte...